H.I.G. BioVentures leads Series C round for ForSight VISION5
ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. Concurrent with the funding, Aaron Davidson of H.I.G. BioVentures has been added to ForSight VISION5's board of directors. Based in Menlo Park, Calif., ForSight VISION5 focuses on developing products that replace eye drops.
16 April 2014•4 mins read
